U.S. FDA Updates LDL-C Lowering Indication for Esperion's NE

– Updated Label Adds Primary Hyperlipidemia, Removes Maximally Tolerated Statin Requirement, Removes Limitation of Use –

Related Keywords

Sheldon Koenig , Tiffany Aldrich , Alexis Callahan , Esperion Therapeutics Inc , Exchange Commission , Drug Administration , Updated Label Adds Primary Hyperlipidemia , Removes Maximally Tolerated Statin Requirement , Removes Limitation , Risk Reduction Labels Remain , Anticipated Approval , Supplemental New Drug Applications , Cholesterol Lowering , Inhibiting Regimen , Esperion Therapeutics , Adverse Event , Contact Information , Region ,